Endovastec

Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (hereinafter referred to as "Endovastec™") is one of the subsidiaries of MicroPort Medical Science and Technology Co., Ltd. (HK: 0853). Established in 2012, it is registered within the Shidai Medical Innovation Park in Shanghai International Medical Zone, China. Endovastec™ successfully listed on the first batch of STAR Market in July 2019, with stock code: 688016.SH. In recent years, the company has been awarded as a high-tech enterprise in Shanghai, a small giant enterprise in science and technology in Shanghai, an enterprise technology center in Shanghai, one of the first batch of specialized, refined, distinctive, and innovative "small giant" enterprises nationwide, and a multinational corporation research and development center; it received the First Prize for Scientific and Technological Progress in Shanghai in 2020 and 2016, the Second Prize for National Scientific and Technological Progress in 2017; it was also awarded the Third Quality Gold Award of Pudong New Area in 2019 and the Shanghai Quality Management Award in 2019. Endovastec™ is an emerging high-tech medical group integrating R&D, manufacturing, sales, and services in the field of aortic and peripheral vascular interventional medical devices. It owns three subsidiaries, namely Lanmai Medical™ (mainly engaged in peripheral venous business), Hongmai Medical™ (mainly engaged in peripheral arterial business), and Tuomai Medical™ (mainly engaged in tumor intervention business). The company has 13 marketed products, mainly including thoracic and abdominal aortic stent grafts, intraoperative stents, drug-coated balloon dilatation catheters, peripheral vascular balloon dilatation catheters, etc., among which five products have obtained CE certification, and six products have entered the national innovative medical device registration green channel, leading the industry. Endovastec™'s products have been introduced into more than 1,300 hospitals across China, with a domestic market share of aortic products reaching 28%, ranking first among Chinese brands for many consecutive years, and exported to countries and regions such as Europe, Latin America, and Southeast Asia. Endovastec™ always takes "providing accessible true goodness and beauty full medical solutions for treating blood circulation diseases" as its mission, committed to building a people-oriented global leading emerging high-tech medical group through technological innovation.